CN114196747A - 一种与代谢相关脂肪性肝病发生发展关联的生物标志物 - Google Patents
一种与代谢相关脂肪性肝病发生发展关联的生物标志物 Download PDFInfo
- Publication number
- CN114196747A CN114196747A CN202010981882.XA CN202010981882A CN114196747A CN 114196747 A CN114196747 A CN 114196747A CN 202010981882 A CN202010981882 A CN 202010981882A CN 114196747 A CN114196747 A CN 114196747A
- Authority
- CN
- China
- Prior art keywords
- mir
- fatty liver
- metabolic
- liver disease
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 31
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 21
- 239000000090 biomarker Substances 0.000 title abstract description 10
- 238000011161 development Methods 0.000 title abstract description 9
- 108091032786 miR-552 stem-loop Proteins 0.000 claims abstract description 73
- 230000014509 gene expression Effects 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 7
- 239000008280 blood Substances 0.000 claims abstract description 7
- 150000002632 lipids Chemical class 0.000 claims abstract description 5
- 239000002679 microRNA Substances 0.000 claims description 36
- 108700011259 MicroRNAs Proteins 0.000 claims description 28
- 238000001514 detection method Methods 0.000 claims description 16
- 108091070501 miRNA Proteins 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 206010067125 Liver injury Diseases 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 108091063755 Homo sapiens miR-552 stem-loop Proteins 0.000 claims description 6
- 206010028851 Necrosis Diseases 0.000 claims description 6
- 230000017074 necrotic cell death Effects 0.000 claims description 6
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 5
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002440 hepatic effect Effects 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 231100000234 hepatic damage Toxicity 0.000 claims description 3
- 238000012317 liver biopsy Methods 0.000 claims description 3
- 230000008818 liver damage Effects 0.000 claims description 3
- VVJYUAYZJAKGRQ-UHFFFAOYSA-N 1-[4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C(O)C1 VVJYUAYZJAKGRQ-UHFFFAOYSA-N 0.000 claims description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 2
- 108010082126 Alanine transaminase Proteins 0.000 claims description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 2
- 102000004420 Creatine Kinase Human genes 0.000 claims description 2
- 108010042126 Creatine kinase Proteins 0.000 claims description 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 claims description 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 108091050172 miR-522 stem-loop Proteins 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 229940045136 urea Drugs 0.000 claims description 2
- 229940116269 uric acid Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 16
- 206010016654 Fibrosis Diseases 0.000 abstract description 11
- 238000003745 diagnosis Methods 0.000 abstract description 11
- 230000004761 fibrosis Effects 0.000 abstract description 10
- 210000002966 serum Anatomy 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 230000004060 metabolic process Effects 0.000 abstract description 7
- 238000009825 accumulation Methods 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 47
- 239000000523 sample Substances 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 231100000753 hepatic injury Toxicity 0.000 description 5
- 230000006372 lipid accumulation Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108091007780 MiR-122 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108091051828 miR-122 stem-loop Proteins 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010981882.XA CN114196747A (zh) | 2020-09-17 | 2020-09-17 | 一种与代谢相关脂肪性肝病发生发展关联的生物标志物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010981882.XA CN114196747A (zh) | 2020-09-17 | 2020-09-17 | 一种与代谢相关脂肪性肝病发生发展关联的生物标志物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114196747A true CN114196747A (zh) | 2022-03-18 |
Family
ID=80644870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010981882.XA Pending CN114196747A (zh) | 2020-09-17 | 2020-09-17 | 一种与代谢相关脂肪性肝病发生发展关联的生物标志物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114196747A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113662951A (zh) * | 2020-05-15 | 2021-11-19 | 中国科学院上海药物研究所 | 一种环烯醚萜苷化合物的医药用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090186353A1 (en) * | 2004-10-04 | 2009-07-23 | Rosetta Genomics Ltd. | Cancer-related nucleic acids |
WO2010103015A1 (en) * | 2009-03-09 | 2010-09-16 | Julius-Maximilians-Universitaet Wuerzburg | Microrna for diagnostic and therapeutic purposes in cardiovascular diseases |
CN104001186A (zh) * | 2013-02-26 | 2014-08-27 | 中国科学院上海药物研究所 | microRNA-552在预防和治疗酒精性肝病中的应用 |
CN110384801A (zh) * | 2018-04-20 | 2019-10-29 | 中国科学院上海药物研究所 | miRNA552簇的微小RNA在治疗LDLC相关代谢性疾病中的应用 |
CN113116918A (zh) * | 2017-12-29 | 2021-07-16 | 中国科学院上海药物研究所 | 靶向PCSK9的microRNA在治疗LDLC相关代谢性疾病中的应用 |
-
2020
- 2020-09-17 CN CN202010981882.XA patent/CN114196747A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090186353A1 (en) * | 2004-10-04 | 2009-07-23 | Rosetta Genomics Ltd. | Cancer-related nucleic acids |
WO2010103015A1 (en) * | 2009-03-09 | 2010-09-16 | Julius-Maximilians-Universitaet Wuerzburg | Microrna for diagnostic and therapeutic purposes in cardiovascular diseases |
CN104001186A (zh) * | 2013-02-26 | 2014-08-27 | 中国科学院上海药物研究所 | microRNA-552在预防和治疗酒精性肝病中的应用 |
CN113116918A (zh) * | 2017-12-29 | 2021-07-16 | 中国科学院上海药物研究所 | 靶向PCSK9的microRNA在治疗LDLC相关代谢性疾病中的应用 |
CN110384801A (zh) * | 2018-04-20 | 2019-10-29 | 中国科学院上海药物研究所 | miRNA552簇的微小RNA在治疗LDLC相关代谢性疾病中的应用 |
Non-Patent Citations (2)
Title |
---|
FAN,L.等: "miR-552-3P modulates transcriptional activities of EXR and LXR to ameliorate hepatic glycolipid metabolism disorder", J.HEPATOL., vol. 74, no. 1, pages 8 - 19, XP086410375, DOI: 10.1016/j.jhep.2020.07.048 * |
王序兵;赵艳洁;于典科;: "微小RNA在酒精致肝损伤中的作用机制研究进展", 环境与职业医学, no. 04 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113662951A (zh) * | 2020-05-15 | 2021-11-19 | 中国科学院上海药物研究所 | 一种环烯醚萜苷化合物的医药用途 |
CN113662951B (zh) * | 2020-05-15 | 2024-02-02 | 中国科学院上海药物研究所 | 一种环烯醚萜苷化合物的医药用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200283851A1 (en) | METHODS OF DETECTING miRNA | |
CN105008551B (zh) | Rna修饰的简易检测方法及用该检测方法的2型糖尿病的检查方法 | |
Yamaura et al. | Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury | |
CN109097477A (zh) | 一种用于乳腺癌诊断的circRNA标志物及其应用 | |
CN111826466B (zh) | 乙型肝炎感染患者或携带者外泌体miRNA分子标志物组合及筛查试剂盒 | |
WO2011012074A1 (zh) | 肝癌检测标记物及其检测方法、试剂盒和生物芯片 | |
EP2818549A1 (en) | Method for classifying test body fluid sample | |
Jiao et al. | MicroRNA-130a expression is decreased in Xinjiang Uygur patients with type 2 diabetes mellitus | |
KR20160145093A (ko) | 이식거부 및 면억억제 요법의 내성을 진단하기 위한 마이크로 리보핵산(miRNA)의 용도 | |
CN110699454A (zh) | 检测样本中mll5基因相对表达量的寡核苷酸、方法和试剂盒 | |
CN114196747A (zh) | 一种与代谢相关脂肪性肝病发生发展关联的生物标志物 | |
US20140378334A1 (en) | Method for quantifying renal markers by assaying urine | |
US20150211069A1 (en) | Marker for detecting myogenic disease and detection method using the same | |
WO2018212288A1 (ja) | パーキンソン病の判定マーカーおよび判定方法 | |
CN112522391B (zh) | hsa_circ_0008961作为痛风诊断标志物的应用 | |
CN114410795A (zh) | 基于miRNA特征标记的肝癌早期检测 | |
CN109182514B (zh) | 肺癌诊断或转移诊断标志物LncRNA Loc729658和试剂盒及其应用 | |
Nateghi et al. | Circulating miR-193b-3p and miR-376a-3p involved in Iranian patients with multiple sclerosis | |
Wickramasinghe et al. | Quantitative real-time PCR as a novel detection method for micro-RNAs expressed by cervical cancer tissue: a review | |
WO2011126105A1 (ja) | 免疫系の異常疾患または関節系の異常疾患への罹患またはこれらの病勢を判定するための検査方法 | |
WO2019000015A1 (en) | SIGNATURES OF MICRO-RNA WITHOUT DEATH CELLS OF BETA ISLANDS BETA CELLS | |
CN108546757B (zh) | Zfpm2-as1在制备胃癌诊断试剂或试剂盒中的应用 | |
CN107312836A (zh) | 小分子RNAmiRNA‑146a‑5p在相关疾病风险诊断中的应用 | |
CN116497112A (zh) | 检测产品、引物或其组合、检测产品及应用 | |
CN113684279A (zh) | 一种诊断骨肉瘤的引物组、试剂盒及检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Ren Jin Inventor after: Huang Ruimin Inventor after: Xie Qing Inventor after: Chen Jing Inventor after: Fan Lei Inventor after: Lai Rongtao Inventor after: Wu Qian Inventor after: Huang Yan Inventor after: Li Yu Inventor after: Xing Guozhen Inventor before: Ren Jin Inventor before: Xie Qing Inventor before: Chen Jing Inventor before: Fan Lei Inventor before: Lai Rongtao Inventor before: Wu Qian Inventor before: Huang Yan Inventor before: Li Yu Inventor before: Xing Guozhen |
|
CB03 | Change of inventor or designer information |